Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
JAMA. 2002 Jan 16;287(3):360-72.

Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

Author information

  • Endocrinology, TMP 534, Yale School of Medicine, Box 208020, New Haven, CT 06520, USA. silvio.inzucchi@yale.edu

Abstract

CONTEXT:

Care of patients with type 2 diabetes has been revolutionized throughout the past several years-first, by the realization of the importance of tight glycemic control in forestalling complications, and second, by the availability of several unique classes of oral antidiabetic agents. Deciphering which agent to use in certain clinical situations is a new dilemma facing the primary care physician.

OBJECTIVE:

To systematically review available data from the literature regarding the efficacy of oral antidiabetic agents, both as monotherapy and in combination.

DATA SOURCES:

A MEDLINE search was performed to identify all English-language reports of unique, randomized controlled clinical trials involving recently available oral agents for type 2 diabetes. Bibliographies were also reviewed to find additional reports not otherwise identified.

STUDY SELECTION AND DATA EXTRACTION:

Studies (63) were included in the analysis if they had a study period of at least 3 months; if each group contained at least 10 subjects at the study's conclusion; and if hemoglobin A(1c) was reported. When multiple dosages of a drug were tested, the results of the highest approved dosage were used. In placebo-controlled trials, hemoglobin A(1c) data are presented as the difference between the change in treated vs placebo subjects.

DATA SYNTHESIS:

Five distinct oral drug classes are now available for the treatment of type 2 diabetes. Compared with placebo treatment, most of these agents lower hemoglobin A(1c) levels approximately 1% to 2%. Equivalent efficacy is usually demonstrated when different agents are compared with one another in the same study population. When they are used in combination, there are additional glycemic benefits. Long-term vascular risk reduction has been demonstrated only with sulfonylureas and metformin.

CONCLUSIONS:

With few exceptions, the available oral antidiabetic agents are equally effective at lowering glucose concentrations. Their mechanisms of action are different, however, and as a result they appear to have distinct metabolic effects. These are reflected in their adverse effect profiles and their effect on cardiovascular risk, which may influence drug choice.

Comment in

PMID:
11790216
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk